Abstract
PURPOSE: To study the efficacy, safety, and outcome of standardized second-line anti-TB treatment of multidrug-resistant tuberculosis (MDR-TB) during pregnancy focusing on maternal and perinatal outcomes. METHODS: Prospective study conducted to evaluate the outcomes of standardized MDR-TB treatment during pregnancy in patients referred to NRITLD from 2003 to 2008. Outcomes are investigated in two categories, namely, maternal and neonatal. RESULTS: Five MDR-TB patients whilst receiving standardized anti-TB regimen became pregnant. We did not change the regimen and all of them did not reveal any adverse effects throughout pregnancy and delivery. No adverse effect occurred for the mothers and the neonates, either. CONCLUSION: Treatment of MDR-TB in pregnancy with standardized second-line regimen could be safe and the rate of successful outcome is acceptable. CLINICAL IMPLICATIONS: Although recommendations for the treatment of pregnant women with pulmonary TB are available, there is no unique guideline for treatment of MDR-TB during pregnancy. The response to treatment is not clear and it has not been yet elucidated which drugs are safe during pregnancy in these patients. In this study all patients received the same standardized regimen of medications. Accordingly, evaluation of patients’ response to treatment and side effects of the treatment could be readily evaluated and compared in a uniform format. DISCLOSURE: Ahmadreza Moradi, No Financial Disclosure Information; No Product/Research Disclosure Information 12:45 PM 2:00 PM Copyright © 2014 American College of Chest Physicians Standardized Second-line Anti-TB Treatment of Multidrug-Resistant Tuberculosis During Pregnancy: Maternal and Neonatal Safety and Outcome Chest. 2010;138(4_MeetingAbstracts):678A. doi:10.1378/chest.9319 FREE TO VIEW Page 1 of 1 7/13/2014 http://journal.publications.chestnet.org/article.aspx?articleid=1086711&resultClick=1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
